High dose intravenous vitamin C plus standard of care chemotherapy doubles survival in metastatic pancreatic cancer, as compared to chemotherapy alone.
This was a small phase 2 trial, which was recently published.
This is unrelated to heart disease. But given the interest in vitamin C in the group, I thought people would find it interesting.
Intravenous vitamin C has a long controversial history in oncology, dating all the way back to initial studies by Linus Pauling and Ewan Cameron in the 1970’s. It failed in the early 2000’s in trials at the NIH as a monotherapy. But this new trial suggests that it might be very promising in pancreatic adenocarcinoma when combined with the right chemotherapy.
Quoted:
“This is a deadly disease with very poor outcomes for patients. The median survival is eight months with treatment, probably less without treatment, and the five-year survival is tiny,” says Joe Cullen, MD, University of Iowa professor of surgery, and radiation oncology, and senior author of the study. “When we started the trial, we thought it would be a success if we got to 12 months survival, but we doubled overall survival to 16 months. The results were so strong in showing the benefit of this therapy for patient survival that we were able to stop the trial early.”


